Table 3 The sensitivity of DMRTA2 to detect BC at different TNM stages in discovery and validation sets
| Â | Discovery set | Validation set | ||||
|---|---|---|---|---|---|---|
Stagea | Bladder cancer (n = 128) | DMRTA2- positive | Sensitivity (95%CI) | Bladder cancer (n = 61) | DMRTA2- positive | Sensitivity (95%CI) |
Total | 137 | 117 | 85.4% (78.1–90.6%) | 79 | 62 | 78.5% (67.5–86.6%) |
Ta | 33 | 22 | 66.7% (48.1–81.4%) | 21 | 12 | 57.1% (34.4–77.4%) |
T1 | 51 | 48 | 94.1% (82.8–98.5%) | 22 | 18 | 81.8% (59.0–94.0%) |
T2 | 28 | 27 | 96.4% (79.8–99.8%) | 12 | 11 | 91.7% (59.8–99.6%) |
T3 | 9 | 7 | 77.8% (40.2–96.1%) | 2 | 2 | 100% (19.8–100%) |
T4 | 7 | 5 | 71.4% (30.3–94.9%) | 4 | 4 | 100% (39.5–100%) |